Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Adnexus Therapeutics Announces Presentation at the American Association for Cancer Research (AACR) on Clinical Product Candidate, CT-322
May 1st, 2007
Adnexus(TM) Therapeutics, Inc. announced the presentation of the abstract "CT-322: A specific VEGFR-2-blocking protein therapeutic agent with activity in preclinical tumor models comparable to pan-specific tyrosine kinase receptor inhibitors sunitinib and sorafenib" at the American Association for Cancer Research (AACR) 2007 annual meeting in Los Angeles, CA. The lead author is Irvith Carvajal, Ph.D., with Eric Furfine, Ph.D., senior vice president of research and preclinical development at Adnexus, presenting at the meeting. CT-322 is a mono-specific blocker of the tyrosine kinase receptor, VEGFR-2, and blocks its activation by all known extracellular ligands; VEGF-A,...
Source: Cancer Weekly (2007-05-01)
|
